In Silico Identification and Verification of the Anticancer Mechanism of TMBM-010 from Oxytropis herba with a Rational Delivery System Design

Patients
diagnosed with gastric cancer often face poor
prognoses
and limited treatment options. Current therapies remain limited, resulting
in significant adverse effects and suboptimal outcomes. Network pharmacology
analysis suggests that TMBM-010, a natural compound, holds the potential
to modulate key pathways in cancer progression. Through network pharmacological
analysis, we identified the anticancer mechanisms of TMBM-010, including
ROS induction, DNA damage, apoptosis, and inhibition of DNA repair
pathways. To enhance the bioavailability and efficacy of TMBM-010,
we developed TMBM-010-loaded nanoparticles (TNPs) and biomimetic nanoparticles
(TNPs@RGD-CM) coated with gastric cancer cell membranes and RGD ligands.
TNPs@RGD-CM demonstrated high stability, excellent biosafety, and
a controlled release profile. In a gastric cancer xenograft model,
TNPs@RGD-CM significantly improved the bioavailability, increased
ROS generation, and enhanced anticancer effects. Our findings demonstrate
that TNPs@RGD-CM augment TMBM-010’s bioactivity in
vivo, effectively targeting cancer cells and suppressing
tumor-promoting pathways. These results suggest that TNPs@RGD-CM represent
a promising nanomedicine strategy for gastric cancer treatment.